To clarify the roles of AKT and BCL-2, we used AKT siRNA or navitoclax, respectively, the latter of which is a pro-apoptotic BH3-mimetic [64] used in clinical trials for melanoma and other cancers, along with BRAF/MEK inhibition [65]. This evidence concerns the gene AKT1 and cancer.